LEAD Coalition submits public comment letter to FDA on study of sex differences

Today, 303 LEAD Coalition member organizations and allies sent a joint public comment letter to the U.S. Food and Drug Administration (FDA) regarding its draft guidance for the study of sex differences in the clinical evaluation of medical products (Docket No. FDA-2024-D-4245). The letter, co-led by the Society for Women’s Health Research, supports the draft […]